

INTERNATIONAL CONCIL FOR HARMONISATION OF TECHNICAL  
REQUIREMENTS FOR PHARMACEUTICALS FOR HUMAN USE

**ICH HARMONISED GUIDELINE**

**GUIDELINE FOR ELEMENTAL IMPURITIES**

**Q3D(R1)**

Draft version

Endorsed on 18 May 2018

*Currently under public consultation*

*At Step 2 of the ICH Process, a consensus draft text or guideline, agreed by the appropriate ICH Expert Working Group, is transmitted by the ICH Assembly to the regulatory authorities of the ICH regions for internal and external consultation, according to national or regional procedures.*

**Q3D(R1)**  
**Document History**

<b>Code</b>	<b>History</b>	<b>Date</b>
Q3D(R1)	Endorsement by the Members of the ICH Assembly under <i>Step 2</i> and release for public consultation (document dated 23 February 2018).	18 May 2018
Q3D	Corrigendum to correct: the modifying factor in the text of the safety assessment for Selenium (changed to 2 instead of 10 consistent with Section 3.1); and two references for consistency in the safety assessments for Barium (deleted reference) and Vanadium (revised reference).	16 December 2014
Q3D	Approval by the Steering Committee under <i>Step 4</i> and recommendation for adoption to the ICH regulatory bodies.	12 November 2014
Q3D	Addition of line numbers to facilitate the provision of comments by stakeholders.	30 September 2013
Q3D	Post sign-off minor editorial corrections including: removal of references to Appendix 5 (pgs i & 13); deletion of redundant text (pg 4); change of Option 2 to Option 2a (pg 10); insertion of omitted text under Safety Limiting Toxicity (pg 35); removal of duplicated redundant text (pg 41); replacing references to “metals” in text and “metal” in Table A.4.7 title with “elementals” and “elements” (pg 73); and deletion of header Table A.4.10 (pg 75).	26 July 2013
Q3D	Post sign-off corrigendum in: <ul style="list-style-type: none"> <li>• Table 4.1 W and Al were removed from the list of included elemental impurities in Class 2B and 3 respectively.</li> <li>• Table A.2.1 the Class for Ni was changed to read 3 instead of 2.</li> </ul>	14 June 2013
Q3D	Approval by the Steering Committee under <i>Step 2b</i> and release for public consultation.	6 June 2013
Q3D	Approval by the Steering Committee under <i>Step 2a</i> .	6 June 2013

**Legal notice:** *This document is protected by copyright and may, with the exception of the ICH logo, be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the document is acknowledged at all times. In case of any adaption, modification or translation of the document, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original document. Any impression that the adaption, modification or translation of the original document is endorsed or sponsored by the ICH must be avoided.*

*The document is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original document be liable for any claim, damages or other liability arising from the use of the document.*

*The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.*

# 1 CADMIUM

## 2 Summary of PDE for Cadmium

Cadmium (Cd)			
	Oral	Parenteral	Inhalation
PDE (µg/day)	5.0	1.7	3.4

## 3 Introduction

4 Cadmium (Cd) is a transition metal whose most abundant naturally-occurring isotope is non-radioactive.  
5 It is found in nature in mineral forms and is obtained for commercial uses principally from cadmium ore  
6 (ATSDR, 2012). Cadmium exists as a salt form in the +2 oxidation state only. Some cadmium salts such  
7 as cadmium chloride, cadmium sulfate and cadmium nitrate are water soluble; other insoluble salts can  
8 become more soluble by interaction with acids, light or oxygen. Cadmium, cadmium oxide, cadmium salts  
9 on borosilicate carrier are used as catalysts in organic synthesis. Silver cadmium alloy is used in the  
10 selective hydrogenation of carbonyl compounds.

## 11 Safety Limiting Toxicity

12 Cadmium has shown to be genotoxic, but not mutagenic and has been acknowledged as a human carcinogen  
13 (Group 1; IARC, 2012). Cadmium and cadmium compounds cause cancer of the lung. Also, positive  
14 associations have been observed between exposure to cadmium and cadmium compounds and cancer of the  
15 kidney and of the prostate.

16 A sensitive endpoint for oral exposure to cadmium and cadmium salts is renal toxicity (Buchet *et al.* 1990).  
17 Skeletal and renal effects are observed at similar exposure levels and are a sensitive marker of cadmium  
18 exposure (ATSDR, 2012).

19 Evidence from numerous epidemiologic studies assessing inhalation exposures to cadmium *via* both  
20 occupational and environmental routes has demonstrated an increased risk of developing cancer (primarily  
21 lung) that correlates with inhalation exposure to cadmium (IARC, 2012; NTP, 1995). ATSDR (2012)  
22 concluded that lung carcinogenesis due to occupational exposure was not unequivocal. Cadmium was  
23 clearly positive for lung tumours in rats; non-significant, non dose dependent in mice; and not observed in  
24 hamsters. An inhalation unit risk estimate of 0.0018/µg/m<sup>3</sup> has been derived by the US EPA (1992);  
25 however, a modifying factor approach may be used for non-mutagenic carcinogens. The US Department of  
26 Labor has reported a Permitted Exposure Level of 5 µg/m<sup>3</sup> for cadmium (Cadmium OSHA, 2004).

## 27 PDE – Oral Exposure

28 A sensitive endpoint for oral exposure to cadmium and cadmium salts is renal toxicity (Buchet *et al.* 1990).  
29 Skeletal and renal effects are observed at similar exposure levels and are a sensitive marker of cadmium  
30 exposure (ATSDR, 2012). A number of oral exposure studies of cadmium in rats and mice showed no  
31 evidence of carcinogenicity. Therefore, the renal toxicity endpoint was used to establish the oral PDE for  
32 cadmium, following the recommendations of ATSDR, an MRL of 0.1 µg/kg for chronic exposure is used  
33 to set the oral PDE. This is consistent with the WHO drinking water limit of 0.003 mg/L/day (WHO, 2011).

34  
35 
$$\text{PDE} = 0.1 \text{ µg/kg/d} \times 50 \text{ kg} = 5.0 \text{ µg/day}$$

36  
37 No modifying factors were applied because they are incorporated into the derivation of the MRL.

## 38 PDE – Parenteral Exposure

39 A 12-week study in rats given daily subcutaneous injections of 0.6 mg/kg Cd, 5 days per week showed  
40 renal damage at week 7 and later (Prozialeck *et al.*, 2009). A single dose level was used in this study. The

41 LOAEL of this study is 0.6 mg/kg based on decreased body weight, increased urine volume and urinary  
42 biomarkers seen at this dose level. This study was used to set the parenteral PDE. In a separate single dose  
43 study where rats were administered 0, 1, 2, 4, 8, 16 or 32 µmol/kg cadmium chloride by the subcutaneous  
44 route, sarcomas were noted at the injection site at the two highest doses at the end of the 72 week observation  
45 period (Waalkes *et al*, 1999). It is uncertain whether the granulomas at the sites of injection over time trap  
46 an unspecified amount of the administered cadmium dose at the injection site. This phenomenon may  
47 decrease the actual parenteral cadmium dose, compared with the calculated parenteral cadmium dose.  
48 Taking into account the modifying factors (F1-F5 as discussed in Appendix 1), and correcting for  
49 continuous dosing from 5 days to 7 days per week (factor of 5/7), the parenteral PDE is calculated as:

50  
51 
$$\text{PDE} = 0.6 \text{ mg/kg} \times 5/7 \times 50 \text{ kg} / 5 \times 10 \times 5 \times 5 \times 10 = 1.7 \text{ µg/day}$$

52  
53 A factor of 5 was chosen for F4 because cadmium is carcinogenic by the inhalation route and granulomas  
54 were observed by the subcutaneous route. These findings are of uncertain relevance. A factor of 10 was  
55 chosen for F5 because a LOAEL was used to set the PDE.

### 56 **PDE – Inhalation Exposure**

57 The United States Department of Labor Occupational Safety and Health Administration has developed a  
58 Permitted Exposure Level of 5 µg/m<sup>3</sup> for cadmium.

59 Taking into account the modifying factors (F1-F5 as discussed in Appendix 1), the inhalation PDE is  
60 calculated as:

61  
62 For continuous dosing = 
$$\frac{5 \text{ µg/m}^3 \times 8 \text{ hr/d} \times 5 \text{ d/wk}}{24 \text{ hr/d} \times 7 \text{ d/wk}} = \frac{1.19 \text{ µg/m}^3}{1000 \text{ L/m}^3} = 0.00119 \text{ µg/L}$$

63  
64  
65 Daily dose = 
$$\frac{0.00119 \text{ µg/L} \times 28800 \text{ L}}{50 \text{ kg}} = 0.685 \text{ µg/kg}$$

66  
67  
68 
$$\text{PDE} = 0.685 \text{ µg/kg} \times 50 \text{ kg} / 1 \times 10 \times 1 \times 1 \times 1 = 3.43 \text{ µg/day}$$

69  
70 A modifying factor for F4 of 1 was chosen based on the potential for toxicity to be mitigated by the possible  
71 species specificity of tumorigenesis, uncertain human occupational tumorigenesis, ambient exposure levels  
72 not expected to be a health hazard, and workplace exposure levels expected to be safe. A larger factor F4  
73 was not considered necessary as the PDE is based on a PEL.

### 74 75 **REFERENCES**

76 ATSDR. Toxicological profile of cadmium. Agency for Toxic Substances and Disease Registry, Public  
77 Health Service, U.S. Department of Health and Human Services, Atlanta, GA. 2012.

78 Buchet JP, Lauwerys R, Roels H, Bernard A, Bruaux P, Claeys F et al. Renal effects of cadmium body  
79 burden of the general population. *Lancet* 1990;336:699-702.

80 Cadmium: OSHA 3136-06R, 2004. (available at <https://www.osha.gov/Publications/osha3136.pdf>;  
81 accessed October 10, 2017)

- 82 IARC. Arsenic, metals, fibres, and dusts: a review of human carcinogens. Monographs on the Evaluation  
83 of Carcinogenic Risks to Humans. International Agency for Research on Cancer, World Health  
84 Organization, Lyon. 2012;100C.
- 85 NTP. Technical report on toxicity studies of cadmium oxide (CAS No. 1306-19-0) administered by  
86 inhalation to F344/N Rats and B6C3F<sub>1</sub> mice. National Toxicology Program, Public Health Service, U.S.  
87 Department of Health and Human Services. 1995.
- 88 Prozialeck WC, Edwards JR, Vaidya VS, Bonventre JV. Preclinical evaluation of novel urinary biomarkers  
89 of cadmium nephrotoxicity. *Toxicol Appl Pharmacol* 2009;238:301-305.
- 90 US EPA. Cadmium. Integrated Risk Information System (IRIS). 1992.
- 91 Waalkes MP, Anver M, Diwan BA. Carcinogenic effects of cadmium in the Noble (NBL/Cr) rat: induction  
92 of pituitary, testicular, and injection site tumors and intraepithelial proliferative lesions of the dorsolateral  
93 prostate. *Toxicol Sci* 1999;52:154-161.
- 94 WHO. Cadmium in drinking-water. Background document for development of WHO Guidelines for  
95 drinking-water quality. World Health Organization. 2011;WHO/SDE/WSH/03.04/80/Rev/1.